Cancers Treatments
Case reference FOI2026/03340
Received 20 July 2026
Published 31 July 2026
Request
I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2026 to the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available? Name of medicine Number patients treated 1.1 Niraparib (Zejula) 1.2 Rucaparib (Rubraca) 1.3 Olaparib (Lynparza) 1.4 Cemiplimab (Libtayo) 1.5 Mirvetuximab soravtansine (Elahere)
Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Name of medicine Number patients treated 2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers 2.2 Olaparib + bevacizumab 2.3 Olaparib monotherapy 2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers 2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin 2.6 Bevacizumab monotherapy
Q3. How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available? Rucaparib Line of Therapy (indication) and NICE TA code Number patients treated 3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055) 3.2 Relapsed platinum-sensitive ovarian cancer (TA1007)
Q4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available? Name of medicine Number patients treated 4.1 Dostarlimab (Jemperli) 4.2 Pembrolizumab (Keytruda) 4.3 Lenvatinib (Lenvima) 4.4 Durvalumab (Imfinzi)
Q5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Name of medicine Number patients treated 5.1 Dostarlimab monotherapy 5.2 Dostarlimab in combination with Chemotherapy 5.3 Pembrolizumab monotherapy 5.4 Pembrolizumab + Lenvatinib in combination 5.5 Pembrolizumab in combination with Chemotherapy 5.6 Durvalumab with Carboplatin and Paclitaxel 5.7 Durvalumab monotherapy 5.8 Durvalumab + Olaparib combination
Q6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? Name of combination or monotherapy dMMR Patients pMMR Patients 6.1 Dostarlimab + Carboplatin + Paclitaxel 6.2 Pembrolizumab + Carboplatin + Paclitaxel 6.3 Pembrolizumab + Lenvatinib 6.4 Dostarlimab as monotherapy at cycle 1 6.5 Dostarlimab as monotherapy maintenance (cycle 7+) 6.6 Pembrolizumab as monotherapy at cycle 1 6.7 Pembrolizumab as monotherapy maintenance (cycle 7+)
Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Tumour type Number patients treated 7.1 Cutaneous Squamous Cell Carcinoma 7.2 Basal Cell Carcinoma 7.3 Non-small Cell Lung Cancer 7.4 Cervical Cancer
Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Treatment intent Number patients treated 8.1 Curative 8.2 Palliative
Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Treatment intent Number patients treated 9.1 Adjuvant
Response
I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2026 to the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available?
Name of medicine Number patients treated
1.1 Niraparib (Zejula) : 11
1.2 Rucaparib (Rubraca) : 9
1.3 Olaparib (Lynparza): 23
1.4 Cemiplimab (Libtayo): 49
1.5 Mirvetuximab soravtansine (Elahere): 0
Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
Name of medicine Number patients treated
2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers: 16
2.2 Olaparib + bevacizumab: < 5
2.3 Olaparib monotherapy: 13
2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers: 16
2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin: 7
2.6 Bevacizumab monotherapy: 7
Q3. How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available?
Rucaparib Line of Therapy (indication) and NICE TA code Number patients treated
3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055): Unable to answer as data not held
3.2 Relapsed platinum-sensitive ovarian cancer (TA1007): Unable to answer as data not held
Q4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available?
Name of medicine Number patients treated
4.1 Dostarlimab (Jemperli) : < 4
4.2 Pembrolizumab (Keytruda): 14
4.3 Lenvatinib (Lenvima): 9
4.4 Durvalumab (Imfinzi): 0
Q5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
Name of medicine Number patients treated
5.1 Dostarlimab monotherapy: 0
5.2 Dostarlimab in combination with Chemotherapy: < 5
5.3 Pembrolizumab monotherapy: < 5
5.4 Pembrolizumab + Lenvatinib in combination: 9
5.5 Pembrolizumab in combination with Chemotherapy: < 5
5.6 Durvalumab with Carboplatin and Paclitaxel: 0
5.7 Durvalumab monotherapy: 0
5.8 Durvalumab + Olaparib combination: 0
Q6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?
Name of combination or monotherapy dMMR Patients pMMR Patients
6.1 Dostarlimab + Carboplatin + Paclitaxel: Unable to answer as data not held
6.2 Pembrolizumab + Carboplatin + Paclitaxel: Unable to answer as data not held
6.3 Pembrolizumab + Lenvatinib: Unable to answer as data not held
6.4 Dostarlimab as monotherapy at cycle 1: Unable to answer as data not held
6.5 Dostarlimab as monotherapy maintenance (cycle 7+): Unable to answer as data not held
6.6 Pembrolizumab as monotherapy at cycle 1
6.7 Pembrolizumab as monotherapy maintenance (cycle 7+): Unable to answer as data not held
Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
Tumour type Number patients treated
7.1 Cutaneous Squamous Cell Carcinoma: Unable to identify as the clinical codes do not capture cell type
7.2 Basal Cell Carcinoma: Unable to identify as the clinical codes do not capture cell type
7.3 Non-small Cell Lung Cancer: Unable to identify as the clinical codes do not capture cell type
7.4 Cervical Cancer: Unable to identify as the clinical codes do not capture cell type
Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
Treatment intent Number patients treated
8.1 Curative: 0
8.2 Palliative: 0
Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
Treatment intent Number patients treated
9.1 Adjuvant: 0
Documents
This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.